This website is being reviewed for updates. Some information is offline. We apologize for any inconvenience.
Skip to main content
Rural Health Information Hub

Rural Health
News by Topic: Health conditions

Sep 12, 2025 - Describes a partnership between the American Heart Association and a rural Arkansas library system to offer blood pressure monitoring kits available for check out. Discusses differences in heart disease prevalence for rural and urban residents.
Source: American Heart Association Newsroom
Sep 10, 2025 - Summarizes recent research findings that rural residents are more likely to experience poor outcomes compared to urban residents following surgery for colon cancer. Greater access to minimally invasive surgery (MIS) for rural patients is identified as a solution for improving surgery outcomes. Discusses challenges with expanding access to MIS.
Source: Bioengineer.org
Aug 22, 2025 - Discusses the suicide risks for veterans, U.S. Department of Veterans Affairs (VA) services that increase access to healthcare, and secure firearm storage as a means to reduce suicide risk.
Source: VA News
Aug 5, 2025 - Request for comments from the Health Resources and Services Administration on an information collection titled "Ending the HIV Epidemic (EHE) Initiative Triannual Report OMB No. 0915-0051—Extension." HRSA proposes to revise a footnote to provide clarity on existing instruction. Comments are due October 6, 2025.
Source: Federal Register
Jul 29, 2025 - The Food and Drug Administration (FDA) has revoked Emergency Use Authorizations issued to Regeneron Pharmaceuticals, Inc., for REGEN-COV (casirivimab and imdevimab administered together); GlaxoSmithKline LLC for sotrovimab; Eli Lilly and Company for bebtelovimab; and AstraZeneca Pharmaceuticals LP for EVUSHELD (tixagevimab co-packaged with cilgavimab). These revocations are effective December 13, 2024.
Source: Federal Register
Jul 28, 2025 - Notice of final rule from the Department of Defense (DOD) Defense Health Agency (DHA) finalizing provisions published in two interim final rules (IFRs) that temporarily added coverage for the treatment use of investigational drugs under U.S. Food and Drug Administration (FDA)-authorized expanded access (EA) programs when for the treatment of coronavirus disease 2019 (COVID-19) and permitted coverage of National Institute of Allergy and Infectious Disease (NIAID)-sponsored clinical trials for the treatment or prevention of COVID-19. Among other things, this rule discusses the DOD's decision not to make permanent the coverage of treatment use of investigational drugs under FDA EA programs while updating language for care associated with their administration and broadens the COVID-19 clinical trial benefit to include coverage of clinical trials sponsored or approved by any National Institutes of Health (NIH) Center or Institute to treat or prevent infectious diseases associated with a pandemic or epidemic. This rule is effective August 27, 2025.
Source: Federal Register